Hayman’s Bass Targets Shire in New Drug Patent Challenges
This article is for subscribers only.
Kyle Bass is expanding his campaign against pharmaceutical companies.
Shire Plc is the newest target of the hedge fund manager’s strategy to challenge drug patents, according to filings Wednesday with the U.S. Patent and Trademark Office. Bass is challenging patents on Lialda and Gattex, according to the filings, which together would have made up 12 percent of Shire’s revenue in 2014.